Press release
Onychomycosis Pipeline Insights, 2022 | In-depth Assessment into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithms, and Key Players by DelveInsight
Onychomycosis Pipeline
Onychomycosis therapy aims to eliminate the infecting fungal organism and restore the nail to its normal state as it grows. Several treatment options are available for treating Onychomycosis, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher treatment cure rates and shorter treatment periods than topical treatments but have adverse side effects such as hepatotoxicity and drug interactions. As per DelveInsight, the Onychomycosis market is anticipated to transform in the coming years owing to the increasing prevalent population of Onychomycosis and the expected entry of new therapies into the market.
"Onychomycosis Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Onychomycosis Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Onychomycosis Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Onychomycosis Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Onychomycosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Onychomycosis Therapeutics Analysis
There are approx. 15+ key companies developing therapies for Onychomycosis. Currently, Moberg Pharma is leading the therapeutics market with its Onychomycosis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Onychomycosis Therapeutics Market Include:
- Moberg Pharma
- Blueberry Therapeutics
- DermBiont
- Sanotize Research and Development
- Meiji Seika Pharma
- NovaBiotics
- Polichem
- Hallux
- Hexima
- Turn Therapeutics
- Mycovia Pharmaceuticals
- CSA BioTech
- Kaken Pharmaceutical
- Turn Therapeutics
And Many More
Onychomycosis Emerging Drugs Covered in the Report Include:
- MOB‐015: Moberg Pharma
- BB2603: Blueberry Therapeutics
- NP213 (Novexatin): NovaBiotics Ltd.
- Hallux Terbinafine Subungual Gel (HSG): Hallux
And Many Others
Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Onychomycosis Current Treatment Patterns
4. Onychomycosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Onychomycosis Late Stage Products (Phase-III)
7. Onychomycosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Onychomycosis Discontinued Products
13. Onychomycosis Product Profiles
14. Onychomycosis Key Companies
15. Onychomycosis Key Products
16. Dormant and Discontinued Products
17. Onychomycosis Unmet Needs
18. Onychomycosis Future Perspectives
19. Onychomycosis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Onychomycosis Pipeline Insights, 2022 | In-depth Assessment into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithms, and Key Players by DelveInsight here
News-ID: 2848901 • Views: …
More Releases from DelveInsight Business Research
Global Pharmaceutical Cartridges Market to grow at a CAGR of 7.39% to reach USD …
According to DelveInsight's analysis, The growth of the pharmaceutical cartridges market is largely fueled by the increasing prevalence of chronic diseases that require long-term and consistent medication use. Moreover, the rising trend of self-administered treatments and the growing preference for home-based healthcare are major contributors to market expansion. Technological advancements in drug delivery systems have further supported this growth by enhancing patient convenience, improving dosage precision, and promoting better treatment…
Global Nucleic Acid Amplification Testing Market to grow at a CAGR of 8.13% by 2 …
According to DelveInsight's analysis, The growing demand for Nucleic Acid Amplification Testing (NAAT) is primarily driven by the increasing prevalence of infectious and genetic diseases. Additionally, the rising incidence of cancer and the expanding R&D efforts by major industry players are further fueling market growth. Together, these factors are expected to support a strong upward trajectory for the NAAT market throughout the forecast period from 2025 to 2032.
DelveInsight's "Nucleic Acid…
Global Cardiac Mapping System Market to grow at a CAGR of 8.37% by 2032, Evaluat …
According to DelveInsight's analysis, The growing incidence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems play a crucial role in the early detection and management of such conditions by providing real-time visualization of the heart's electrical activity, thereby reducing the risk of severe complications like stroke and heart failure. Moreover, the rising adoption of minimally invasive procedures,…
Global Graft Preparation System Market to grow at a CAGR of 4.17% to reach USD 3 …
According to DelveInsight's analysis, The demand for graft preparation systems is experiencing notable growth, primarily driven by the rising incidence of bone disorders and skin-related conditions. Moreover, the increasing number of surgical procedures worldwide, coupled with expanding R&D initiatives and strategic collaborations among leading market players, is further fueling market expansion. Together, these factors are expected to create a strong growth outlook for the graft preparation system market during the…
More Releases for Onychomycosis
Rising Diabetic Population Fuels Onychomycosis Market Growth: Powering Innovatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Onychomycosis Market Through 2025?
In recent times, the onychomycosis market has experienced robust growth. It is projected to expand from $3.63 billion in 2024 to $3.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.4%. The growth seen in…
Rising Diabetic Population Fuels Onychomycosis Market Growth: A Significant Driv …
The Onychomycosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Onychomycosis Market Size and Projected Growth Rate?
The market for onychomycosis has seen substantial growth in recent times. The market size is predicted to rise from $3.63 billion in 2024 to $3.83 billion…
Onychomycosis Market Insights and Development Trends
The Onychomycosis Market Is Set To Grow At An Estimated CAGR Of 8.5% From 2025 To 2034, Rising From $7.8 Billion In 2024 To $14.5 Billion By 2034.
On March 21, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Onychomycosis market goods. The market study excludes key regions that are accelerating marketization. This section also gives…
Onychomycosis Treatment Market Size & Share Analysis
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Onychomycosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $4.73 billion In 2028 At…
Onychomycosis Therapeutics Market - Empowering Nail Wellness, Inspiring Beautifu …
Newark, New Castle, USA - new report, titled Onychomycosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Onychomycosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Onychomycosis Therapeutics market. The report offers an overview of the market, which…
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin…
